- Home
- PRZO vs CMND Comparison
PRZO vs CMND Comparison
Compare PRZO & CMND Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | PRZO | CMND |
|---|---|---|
| Founded | 2014 | 2017 |
| Country | Israel | Canada |
| Employees | N/A | N/A |
| Industry | | Biotechnology: Pharmaceutical Preparations |
| Sector | | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 24.6M | 1.4M |
| IPO Year | 2022 | 2021 |
Fundamental Metrics
Financial Performance| Metric | PRZO | CMND |
|---|---|---|
| Price | $1.13 | $0.68 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | ★ 852.2K | 84.6K |
| Earning Date | 01-01-0001 | 01-01-0001 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $0.53 | $0.07 |
| 52 Week High | $2.15 | $3.25 |
Technical Indicators
Market Signals| Indicator | PRZO | CMND |
|---|---|---|
| Relative Strength Index (RSI) | 45.10 | 25.59 |
| Support Level | $1.11 | $0.08 |
| Resistance Level | $1.47 | $1.10 |
| Average True Range (ATR) | 0.09 | 0.12 |
| MACD | -0.01 | -0.01 |
| Stochastic Oscillator | 12.70 | 8.64 |
Price Performance
Historical ComparisonAbout PRZO ParaZero Technologies Ltd.
ParaZero Technologies Ltd is an aerospace company that is focused on drone safety systems and engaged in the business of designing, developing, and providing autonomous parachute safety systems for commercial drones, also known as unmanned aerial systems. The ParaZero SafeAir system of the company applies real-time data analytics to identify and mitigate flight risks autonomously and increase safety for bystanders while protecting the loss of expensive drones, equipment, and payloads.
About CMND Clearmind Medicine Inc.
Clearmind Medicine Inc is a clinical-stage pharmaceutical company engaged in Phase I/IIa clinical trials of novel psychedelic medicines. The Company focuses on developing treatments for mental health disorders, including alcohol use disorder (AUD), binge drinking, and eating disorders. Its activities are centered on the research and development of 5-methoxy-2-aminoindane (MEAI). It operates through a single research and development segment, which is conducted in Israel.